Eton Pharmaceuticals Inc
Company Profile
- Business description- Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. 
- Contact- 21925 West Field Parkway 
 Suite 235
 Deer ParkIL60010-7278
 USA- T: +1 847 787-7361 
- Sector- Healthcare - Stock type- Defensive 
- Industry- Drug Manufacturers - Specialty & Generic - Fiscal Year End- 31 December 2025 - Employees- 31 
Stocks News & Analysis
stocks
Undervalued ASX share with plan to mitigate tariff risk
stocks
Earnings up but shares overvalued for ASX gold miner
stocks
Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%
Morningstar Investment Ideas
Markets
| Index | Last price | Change | % Change | 
|---|---|---|---|
| All Ordinaries | 9,295.80 | 26.20 | -0.28% | 
| CAC 40 | 8,216.58 | 22.60 | -0.27% | 
| DAX 40 | 24,278.63 | 30.15 | -0.12% | 
| Dow JONES (US) | 47,706.65 | 162.06 | 0.34% | 
| FTSE 100 | 9,696.74 | 42.92 | 0.44% | 
| HKSE | 26,346.14 | 87.56 | -0.33% | 
| NASDAQ | 23,827.49 | 190.04 | 0.80% | 
| Nikkei 225 | 50,219.18 | 293.14 | -0.58% | 
| NZX 50 Index | 13,402.66 | 11.07 | 0.08% | 
| S&P 500 | 6,890.95 | 15.79 | 0.23% | 
| S&P/ASX 200 | 9,012.50 | 16.30 | -0.18% | 
| SSE Composite Index | 3,988.22 | 8.72 | -0.22% |